ATEA PHARMACEUTICALS INC (AVIR) — insider trading
Health Care · NASDAQ
ATEA PHARMACEUTICALS INC (AVIR) has 37 reported SEC Form 4 insider transactions in our data, including 2 open-market purchases among the most recent 37 (latest 2026-06-18).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-18 | KIRSCH ARTHUR S | Director | Grant / award / vesting (derivative) | 37,700 | $0.00 | $0 | Form 4 |
| 2026-06-18 | KIRSCH ARTHUR S | Director | Grant / award / vesting (derivative) | 26,700 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Adams Jerome M. | Director | Grant / award / vesting (derivative) | 37,700 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Adams Jerome M. | Director | Grant / award / vesting (derivative) | 26,700 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Adams Jerome M. | Director | Option exercise / conversion (derivative) | 29,600 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Adams Jerome M. | Director | Option exercise / conversion | 29,600 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Murphy Polly A. | Director | Grant / award / vesting (derivative) | 37,700 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Murphy Polly A. | Director | Grant / award / vesting (derivative) | 26,700 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Murphy Polly A. | Director | Option exercise / conversion (derivative) | 29,600 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Murphy Polly A. | Director | Option exercise / conversion | 29,600 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Polsky Bruce | Director | Grant / award / vesting (derivative) | 37,700 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Polsky Bruce | Director | Grant / award / vesting (derivative) | 26,700 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Polsky Bruce | Director | Option exercise / conversion (derivative) | 29,600 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Polsky Bruce | Director | Option exercise / conversion | 29,600 | $0.00 | $0 | Form 4 |
| 2026-06-18 | DUNCAN BARBARA GAYLE | Director | Grant / award / vesting (derivative) | 37,700 | $0.00 | $0 | Form 4 |
| 2026-06-18 | DUNCAN BARBARA GAYLE | Director | Grant / award / vesting (derivative) | 26,700 | $0.00 | $0 | Form 4 |
| 2026-06-18 | DUNCAN BARBARA GAYLE | Director | Option exercise / conversion (derivative) | 29,600 | $0.00 | $0 | Form 4 |
| 2026-06-18 | DUNCAN BARBARA GAYLE | Director | Option exercise / conversion | 29,600 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Berman Howard | Director | Grant / award / vesting (derivative) | 37,700 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Berman Howard | Director | Grant / award / vesting (derivative) | 26,700 | $0.00 | $0 | Form 4 |
| 2026-06-18 | BERGER FRANKLIN M | Director | Grant / award / vesting (derivative) | 37,700 | $0.00 | $0 | Form 4 |
| 2026-06-18 | BERGER FRANKLIN M | Director | Grant / award / vesting (derivative) | 26,700 | $0.00 | $0 | Form 4 |
| 2026-06-18 | BERGER FRANKLIN M | Director | Option exercise / conversion (derivative) | 29,600 | $0.00 | $0 | Form 4 |
| 2026-06-18 | BERGER FRANKLIN M | Director | Option exercise / conversion | 29,600 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Lucidi Bruno | Director | Grant / award / vesting (derivative) | 37,700 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Lucidi Bruno | Director | Grant / award / vesting (derivative) | 26,700 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Lucidi Bruno | Director | Option exercise / conversion (derivative) | 29,600 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Lucidi Bruno | Director | Option exercise / conversion | 29,600 | $0.00 | $0 | Form 4 |
| 2026-05-18 | Murphy Polly A. | Director | Open-market purchase | 6,100 | $4.17 | $25.4K | Form 4/A |
| 2026-03-11 | Corcoran Andrea | Officer (See Remarks) | Option exercise / conversion (derivative) | 60,000 | $0.00 | $0 | Form 4 |
| 2026-03-11 | Corcoran Andrea | Officer (See Remarks) | Option exercise / conversion | 60,000 | $1.24 | $74.4K | Form 4 |
| 2026-01-31 | Horga Maria Arantxa | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 173,500 | $0.00 | $0 | Form 4 |
| 2026-01-31 | Horga Maria Arantxa | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 9,750 | $0.00 | $0 | Form 4 |
| 2026-01-31 | Horga Maria Arantxa | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 41,533 | $0.00 | $0 | Form 4 |
| 2026-01-31 | Horga Maria Arantxa | Officer (Chief Medical Officer) | Shares withheld for taxes / exercise cost | 16,073 | $4.24 | $68.1K | Form 4 |
| 2026-01-31 | Horga Maria Arantxa | Officer (Chief Medical Officer) | Option exercise / conversion | 51,283 | — | — | Form 4 |
| 2025-05-18 | Murphy Polly A. | Director | Open-market purchase | 6,100 | $4.17 | $25.4K | Form 4 |
Ask the chat about AVIR's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ATEA PHARMACEUTICALS INC (AVIR).
Last updated 2026-06-18 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.